title: Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.
abstract: BACKGROUND
  Phyllanthus species for patients with chronic hepatitis B virus (HBV) infection have been assessed in clinical trials, but no consensus regarding their usefulness exists. When compared with placebo or no intervention, we were unable to identify convincing evidence that phyllanthus species are beneficial in patients with chronic hepatitis B. Some randomised clinical trials have compared phyllanthus species versus antiviral drugs.
  
  
  OBJECTIVE
  To evaluate the benefits and harms of phyllanthus species compared with antiviral drugs for patients with chronic HBV infection.
  
  
  METHODS
  Searches were performed in The Cochrane Hepato-Biliary Gorup Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expended, and the Chinese Biomedical CD Database, China Network Knowledge Information, Chinese Science Journal Database, TCM Online, and Wanfang Database. Conference proceedings in Chinese were handsearched. All searches were conducted until 31st October 2012.
  
  
  METHODS
  Randomised clinical trials comparing phyllanthus species with antiviral drugs for patients with chronic HBV infection. We included trials irrespective of blinding, publication status, or language.
  
  
  METHODS
  Two authors selected the trials and extracted the data independently. The RevMan software was used for statistical analysis of dichotomous data with risk ratio (RR) with 95% confidence intervals (CI). We assessed the risk of bias to control for systematic errors. We calculated the number of patients needed (required information size) to be randomised in order to make reliable conclusions. We assessed the cumulative findings with trial sequential analysis to control for random errors.
  
  
  RESULTS
  We identified five randomised clinical trials with 290 patients. All trials were considered to have high risk of bias. Patients in the experimental group received compound phyllanthus for three months to 12 months. Patients in the antiviral drug group received lamivudine, interferon alpha, thymosin, or thymosin alpha 1. None of the trials reported mortality, hepatitis B-related morbidity, quality of life, or liver histology. Phyllanthus seemed to have a superior effect on clearance of serum HBeAg at the end of treatment in conventional meta-analysis (RR 0.76; 95% CI 0.64 to 0.91, P = 0.002; I(2) = 0%), but not when trial sequential analysis was applied. Phyllanthus had no significant effect on clearance of serum HBsAg (RR 1.00; 95% CI 0.93 to 1.08, P = 0.92; I(2) = 0%) or HBV DNA (RR 0.83; 95% CI 0.53 to 1.31, P = 0.43; I(2) = 70%) when compared with antiviral drugs. Data on HBeAg seroconversion was reported in one trial and no significant difference was found comparing phyllanthus versus lamivudine (RR 0.89; 95% CI 0.71 to 1.11). No data were reported on adverse events in the five trials.
  
  
  CONCLUSIONS
  There is currently insufficient evidence to support or refute the use of phyllanthus for patients with chronic hepatitis B virus infection. Researchers who are interested in conducting further randomised clinical trials on phyllanthus ought to monitor both beneficial and harmful effects and should primarily test the herb against placebo in addition to antiviral drugs that are known to offer more benefit than harm. Only in this way new interventions can be assessed without compromising personal ethical considerations.
authors: Centre for Evidence-Based ChineseMedicine, Beijing University of ChineseMedicine, Beijing, China.
authors: Yun
authors: Y
authors: Xia
authors: Hui
authors: H
authors: Luo
authors: Jian Ping
authors: JP
authors: Liu
authors: Christian
authors: C
authors: Gluud
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D029803:Phyllanthus; D008517:Phytotherapy; D016032:Randomized Controlled Trials as Topic; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D019259:Lamivudine; D013947:Thymosin; D000077596:Thymalfasin
references: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1997 Sep;11(3):282-5
references: 15617349
references: Hepatology. 2009 Sep;50(3):661-2
references: 19714720
references: J Gastroenterol Hepatol. 2003 Mar;18(3):239-45
references: 12603522
references: BMJ. 2001 Jul 7;323(7303):42-6
references: 11440947
references: Int J Technol Assess Health Care. 2003 Fall;19(4):591-603
references: 15095765
references: Hepatology. 1991 Sep;14(3):409-15
references: 1874487
references: JAMA. 1995 Feb 1;273(5):408-12
references: 7823387
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004790
references: 16625613
references: Stat Med. 1987 Oct-Nov;6(7):753-60
references: 3321314
references: Lancet. 1998 Aug 22;352(9128):609-13
references: 9746022
references: Expert Opin Biol Ther. 2009 May;9(5):593-608
references: 19392576
references: J Hepatol. 2007 Apr;46(4):734-42
references: 17316871
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: J Ethnopharmacol. 2006 Mar 8;104(1-2):79-86
references: 16236476
references: J Clin Epidemiol. 2008 Jan;61(1):64-75
references: 18083463
references: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006481
references: 18677780
references: Ann N Y Acad Sci. 2007 Sep;1112:225-34
references: 17600290
references: N Engl J Med. 2003 Feb 27;348(9):808-16
references: 12606735
references: Liver Int. 2005 Jun;25(3):472-89
references: 15910483
references: Ann Intern Med. 2012 Sep 18;157(6):429-38
references: 22945832
references: Proc Natl Acad Sci U S A. 1987 Jan;84(1):274-8
references: 3467354
references: Antiviral Res. 1995 Aug;27(4):367-74
references: 8540756
references: Eur J Clin Invest. 1997 Nov;27(11):908-15
references: 9395786
references: Value Health. 2009 Nov-Dec;12 Suppl 3:S89-92
references: 20586991
references: Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008960
references: 21491412
references: J Cell Biochem. 2006 Mar 1;97(4):795-812
references: 16237706
references: Gastroenterology. 2012 May;142(6):1360-1368.e1
references: 22537444
references: Mol Phylogenet Evol. 2005 Jul;36(1):112-34
references: 15904861
references: Health Technol Assess. 2012 Sep;16(35):1-82
references: 22989478
references: J Hepatol. 2009 Feb;50(2):227-42
references: 19054588
references: J Pharm Pharmacol. 2006 Dec;58(12):1559-70
references: 17331318
references: Med Res Rev. 1998 Jul;18(4):225-58
references: 9664291
references: Eur J Clin Invest. 1996 Dec;26(12):1069-76
references: 9013081
references: BMJ. 2008 Mar 15;336(7644):601-5
references: 18316340
references: J Clin Epidemiol. 2008 Aug;61(8):763-9
references: 18411040
references: Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033
references: 23235689
references: N Engl J Med. 1997 Jun 26;336(26):1855-9
references: 9197213
references: Ann Intern Med. 2001 Dec 4;135(11):982-9
references: 11730399
references: J Hepatol. 2003 Feb;38(2):215-22
references: 12547411
references: BMC Med Res Methodol. 2009 Dec 30;9:86
references: 20042080
references: J Viral Hepat. 2001 Sep;8(5):358-66
references: 11555193
references: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD000100
references: 16235273
references: Aliment Pharmacol Ther. 2003 Aug 1;18(3):339-45
references: 12895219
references: Hepatol Int. 2008 Sep;2(3):263-83
references: 19669255
references: J Viral Hepat. 2010 Mar;17 Suppl 1:10-7
references: 20586929